Ipsen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.12.24	Ipsen And Biomunex Reach Licensing Agreement For MAIT Cell Engager In Immuno-Oncology (RTTNews)
23.10.24	Ipsen Q3 Sales Increase; Lifts FY24 Outlook - Quick Facts (RTTNews)
03.10.24	Eton Pharma To Buy SPIGFD Drug Increlex From Ipsen (RTTNews)
23.09.24	Ipsen: European Commission Approves Kayfanda - Quick Facts (RTTNews)
20.09.24	Ipsen: European Commission Grants Conditional Marketing Authorization For Iqirvo (RTTNews)
25.07.24	Ipsen Posts Higher H1 Profit, Signs New Partnership With Day One For Tovorafenib (RTTNews)
11.07.24	Ipsen And Foreseen Biotechnology Strike Deal For FS001, Antibody-Drug Conjugate (RTTNews)
04.07.24	HUTCHMED Announces NDA Acceptance For Tazemetostat In China - Quick Facts (RTTNews)
02.07.24	Ipsen Expands Exelixis Collaboration For Cabometyx In Advanced Neuroendocrine Tumors (RTTNews)
11.06.24	FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo (Benzinga)
11.06.24	Ipsen's Iqirvo Secures FDA Accelerated Approval For Primary Biliary Cholangitis Treatment (RTTNews)
07.06.24	Ipsen Reaches Deal To Advance Precision T Cell Engagers From Marengo's Tri-STAR Platform (RTTNews)
03.06.24	Ipsen Initiates Share Buy-back Program - Quick Facts (RTTNews)
24.04.24	Ipsen Q1 Total-sales Up 13.3% At CER; Confirms 2024 Financial Guidance (RTTNews)
22.04.24	Ipsen, Skyhawk Therapeutics To Develop RNA-Modulating Molecules For Rare Neurological Disorders (RTTNews)
02.04.24	Ipsen Secures Exclusive Global Rights Of Sutro Biopharma's STRO-003 ADC In Up To $900 Mln Deal (RTTNews)
08.02.24	Ipsen FY23 Profit Flat, Sales Rise; Sees Growth In FY24, Backs Mid-term View (RTTNews)
31.01.24	Biotech Stocks Facing FDA Decision In February 2024 (RTTNews)
07.12.23	Ipsen : FDA Grants Priority Review To Elafibranor NDA For Rare Cholestatic Liver Disease Treatment (RTTNews)
13.11.23	Ipsen Says Health Canada Approved Bylvay To Treat Pruritus Due To PFIC (RTTNews)
13.11.23	Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC) (PR Newswire)
26.10.23	Ipsen 9-month Sales Up (RTTNews)
31.07.23	Biotech Stocks Facing FDA Decision In August 2023 (RTTNews)
30.06.23	Ipsen, GENFIT Reveal Positive Phase III Trial Results Of Elafibranor In Patients With PBC (RTTNews)
29.06.23	FDA Panel Votes In Favor Of Ipsen's Palovarotene For Ultra-rare Bone Disease (RTTNews)
31.05.23	IPSEN Issues Regulatory Framework Of Share Repurchase Program - Quick Facts (RTTNews)
19.05.23	Ipsen: Dysport Receives Positive Opinion In Europe (RTTNews)
27.01.23	Ipsen: CHMP Recommends Not To Grant Marketing Authorization For Palovarotene As Treatment For FOP (RTTNews)
27.01.23	Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U. (Businesswire)
20.01.23	Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI (Businesswire)
09.01.23	Ipsen To Buy Albireo; Acquisition To Provide Immediate Incremental Sales (RTTNews)
09.01.23	Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases (Businesswire)
23.12.22	Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva (Businesswire)
09.11.22	Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (Businesswire)
27.10.22	Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance (Businesswire)
25.10.22	Ipsen : FDA Postpones Palovarotene Advisory Committee Meeting (RTTNews)
25.10.22	Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting (Businesswire)
30.09.22	Biotech Stocks Facing FDA Decision In October 2022 (RTTNews)
12.08.22	Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology (Businesswire)
05.08.22	Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 (Businesswire)
03.08.22	Merrimack: Ipsen's Phase 3 Trial Of Onivyde Fails To Meet Primary Endpoint (RTTNews)
03.08.22	Ipsen: Phase III RESILIENT Trial Evaluating Onivyde Fails To Meet Primary Endpoint (RTTNews)
03.08.22	Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer (Businesswire)
01.08.22	Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic (Businesswire)
29.06.22	Ipsen Announces FDA Priority Review For Palovarotene NDA In Patients With Rare Genetic Disorder (RTTNews)
29.06.22	Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission (Businesswire)
27.06.22	Ipsen To Acquire Epizyme For $1.45/share In Cash - Quick Facts (RTTNews)
27.06.22	Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology (Businesswire)
09.06.22	Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury (Businesswire)
01.06.22	Ipsen Initiates a Share Buy-Back Program to Cover Its Employee Free Share-Allocation Plan (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.28	1.50 %	K V
Holcim	87.20	1.28 %	K V
UBS Group	27.04	1.24 %	K V
Roche Hldg G	250.40	1.21 %	K V
Swiss Re	130.05	1.21 %	K V
Part Grp Hldg	1’217.00	0.50 %	K V
Lonza Grp	532.00	0.19 %	K V
Sonova Hldg	296.00	0.14 %	K V
Nestle	74.08	0.14 %	K V
Geberit	511.60	-0.51 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ipsen (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten